Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture
about
The NMR structure of estrone (Es)-tethered tandem DNA duplex: [d(5'pCAGCp3')-Es] + [Es-d(5'pTCCA3')]: d(5'pTGGAGCTG3')Induction of chronic human immunodeficiency virus infection is blocked in vitro by a methylphosphonate oligodeoxynucleoside targeted to a U3 enhancer elementAntisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cellsLong-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioatesT30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1Rapid routes of synthesis of oligonucleotide conjugates from non-protected oligonucleotides and ligands possessing different nucleophilic or electrophilic functional groups.Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides.Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains.Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide5'-Cholesteryl-phosphorothioate oligodeoxynucleotides: potent inhibition of methotrexate transport and antagonism of methotrexate toxicity in cells containing the reduced-folate carrier.Fluorescence energy transfer as a probe for nucleic acid structures and sequences.Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy.The estimation of distances between specific backbone-labeled sites in DNA using fluorescence resonance energy transferModification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacyMechanisms of the inhibition of reverse transcription by antisense oligonucleotides.Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells.Bioconjugation of oligonucleotides for treating liver fibrosis.Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipidsAntisense agents in cancer research and therapeutics.Guanidinium-cholesterol cationic lipids: efficient vectors for the transfection of eukaryotic cells.Innovations in the use of antisense oligonucleotides.Hybrid lipid oligonucleotide conjugates: synthesis, self-assemblies and biomedical applications.Oligoribonucleotides containing 2',5'-phosphodiester linkages exhibit binding selectivity for 3',5'-RNA over 3',5'-ssDNA.Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates.A 5'-cap for DNA probes binding RNA target strands.Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR elementAntisense pro-drugs: 5'-ester oligodeoxynucleotidesSite-specific introduction of functional groups into phosphodiester oligodeoxynucleotides and their thermal stability and nuclease-resistance properties.Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptakeDNA-based micelles: synthesis, micellar properties and size-dependent cell permeability.Intracellular oligonucleotide hybridization detected by fluorescence resonance energy transfer (FRET).Template controlled coupling and recombination of oligonucleotide blocks containing thiophosphoryl groupsEffective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol.Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions.Synthesis and hybridization properties of oligonucleotides containing 2'-O-modified ribonucleotides.Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups.Treatment of AIDS with drugs targeted to inhibit different stages of the HIV life cycle.Hybridization and dissociation rates of phosphodiester or modified oligodeoxynucleotides with RNA at near-physiological conditions.Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates.Interaction of cholesterol-conjugated alkylating oligonucleotide derivatives with cellular biopolymers.
P2860
Q27748812-5998F30A-CE96-451F-AA0D-E8C28096B60CQ28323598-38D8FF31-95C7-4CA4-A49C-7802469B91E4Q28369354-DF64E70C-9A61-4EE6-B4D1-10DFC791BC28Q28378692-1D3DAA61-85E0-4740-A547-35DC9BC1AC0FQ28378782-54963971-C99B-4F5B-8D9F-40F2FB76DD2CQ30980249-8B14DD77-D3CC-43B8-AED8-F75483AF727BQ33563974-EF2D3589-4EFF-404A-8A05-2D699A6CA556Q33573152-A1FABB26-5AA1-4195-9724-62AB547EAE42Q33978043-FDF5DA40-88A8-400B-B052-BD27F1C041B5Q34772710-B1800CFA-12A1-43F9-BDE8-F6F78D2243B4Q34811094-7174F6E2-1DBE-4D5C-88B1-22358B56B91FQ35241689-14202666-BEB7-461F-81CA-E56CCC8CB31DQ35930856-4688EA73-05F6-433B-87DF-9F9FF883B2A4Q36087670-0F3924DA-A99C-43A0-B4E5-0598AC873C2AQ36798960-7FCD78F2-285A-4F3C-A234-C53DEA6F0399Q36920080-13B8E997-35F2-4D78-B08B-7E4CCFCAB039Q37043515-521B4C74-09DA-4ABC-AA5C-D8D478BB58EDQ37127281-188EAC79-86FC-4D84-AA0F-0C92052A01F0Q37220809-471FD370-21CB-42F0-A66B-A111D0D8E422Q37360169-289D1247-808A-46FA-821F-E38A28BF0C9DQ37783034-E285D920-5726-43BC-A67A-66BB6FB405E4Q37879557-FC4445B0-3ABD-4BE6-B8A7-17CD00173597Q38315278-72CB01FF-E6C8-4FB7-A922-2CD60594DF0CQ38326062-463A1022-224C-4EA1-B17D-DE7DF0679C82Q38331760-AFC51FD2-79F3-4231-BBEA-CD78CD23E94BQ38334658-CCBAE403-B212-4FE1-979B-92373D6E9584Q38572359-6BD446DD-D945-42AE-8AC6-674A0ADCF386Q39720643-AAF914C5-A89C-410F-AF61-7BBF5957603EQ39728591-DF071010-AEB4-4564-9680-BE1CE408303CQ39738354-7F49A82E-17A0-4E67-A119-13118C93C490Q40398651-834CC5E5-B558-4670-BC89-764E1E317AF1Q40406021-826B2C30-6DDB-4DFE-A384-8383321C992DQ40411803-7028623C-733F-4120-A3EC-511CCAA0538BQ40412118-1545E9A8-26CB-4B6A-B03E-9BFFD95AEEA6Q40415620-B18F5ECA-C61C-4B3A-9D0B-7E3004AAECCDQ40423002-C1C4A4AE-1B95-45A9-88F3-F743497B2487Q40468453-39A6AD08-DF5A-4B96-B1BD-36D28EE9523BQ40510222-31B2790A-60E2-49BD-87D8-2A34E37D91CCQ40517947-87BABD51-5685-47CC-B59C-7F420EB97C57Q41635484-6A78A794-582A-4CB1-B8ED-D25EB171A8B4
P2860
Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
name
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@ast
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@en
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@nl
type
label
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@ast
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@en
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@nl
prefLabel
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@ast
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@en
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@nl
P2093
P2860
P356
P1476
Cholesteryl-conjugated oligonu ...... ficiency virus in cell culture
@en
P2093
P2860
P304
P356
10.1073/PNAS.86.17.6553
P407
P577
1989-09-01T00:00:00Z